Chemotherapy regimen: ICE

Agents involved
- Etoposide 100 mg/m^2 IV in 500 mL of NS Days 1 – 3
- Carboplatin Target AUC of 5 in 100 mL of D5W Day 2
- Ifosfamide/Mesna 5/5 g/m^2 in 1000 mL of NS Day 2

Summary of possible interactions with antiretroviral agents

Antiretroviral agents to avoid
- Avoid zidovudine-containing regimens (Retrovir®, Combivim®, Trizivir®) as additive hematologic toxicity is possible(1-3). (Quality of Evidence: very low)

If the patient is on one of the antiretroviral agents mentioned above, contact the HIV physician to request a change/substitution of antiretroviral agents.

Enzyme inhibition interactions
- Possible increased etoposide toxicity (infections, neutropenia, mucositis) (4, 5) (Quality of Evidence: moderate)
- Possible decreased efficacy of ifosfamide (6, 7) (Quality of Evidence: very low; theoretical, unknown clinical significance)
  - Contact the HIV physician to request a change/substitution to a non-PI, non-NNRTI based regimen

Enzyme induction interactions
- Possible decreased efficacy of etoposide (6, 7)
- Possible increased toxicity of ifosfamide (6, 7)

Enzyme neutral agents: unlikely to interact
- According to the metabolic profile of the individual agents, pharmacokinetic interactions are unlikely to occur. Nonetheless, additive toxicity remains possible with certain agents depending on the safety profile.

Laboratory interactions
- Cobicistat (Stribild®, Tybost®), rilpivirine (Edurant®, Complera®) and dolutegravir (Tivicay®) containing regimens will increase serum creatinine by approximately 7-15 µmol/L during the first 4 weeks of treatment initiation due to inhibition of renal creatinine secretion. This does not reflect an actual decrease in renal function, and the effect is quickly reversible upon drug discontinuation.

Note: if interruption of any antiretroviral agent is considered necessary, contact the HIV physician to determine appropriate cessation of the antiretroviral therapy (certain antiretroviral regimens require sequential cessation of antiretroviral agents while others require immediate cessation of all antiretroviral agents at once). If treatment for hepatitis B (HBV) co-infection is required, consult the HIV physician, since some antiretroviral agents have activity against both HIV and HBV.
**Literature**

No studies or case reports specifically regarding ICE and antiretroviral agents were found. Data available from other regimens including similar antineoplastic agents are presented below.

**CDE**

Several studies regarding the concomitant use of CDE (cyclophosphamide 1 200 mg/m²; doxorubicin 50 mg/m²; etoposide 240 mg/m² continuous infusion over 4 days q4weeks) and antiretroviral therapy were available. Etoposide dose is slightly lower in comparison to ICE. One study in 46 patients who received CDE for treatment of AIDS related lymphoma compared those who received a PI based combination antiretroviral therapy (cART) to those who received a non-PI based cART. The groups showed similar overall response and survival rates; however, an increased risk of severe infections (48% vs 25%; p<0.01) and neutropenia (54% vs 38%; p =0.05) was observed in patients on a PI based cART compared to those on a non-PI based cART(4). Another study in 12 patients showed an increased risk of severe mucositis (67% vs 12%; p<0.01) when patients received a saquinavir-based cART in comparison to a historical cohort not on cART(5).

**CODOX-M/IVAC**

One case report described good tolerability of etoposide and ifosfamide after severe vincristine toxicity. The patient received CODOX-M for the treatment of Burkitt’s lymphoma while on a lopinavir/ritonavir based cART. He developed paralytic ileus that lasted 10 days. Two weeks after his recovery, IVAC (ifosfamide 7.5 g/m², etoposide 300 mg/m² IV, cytarabine 8 g/m² IV per cycle) was administered and was well tolerated. The dose of ifosfamide used is higher than that used in ICE although the etoposide dose is the same. Subsequent cycles of CODOX-M were administered with etoposide (dose not specified) replacing the vincristine component and was well tolerated.(8)

**DA-EPOCH**

Two cases described good tolerability of dose-adjusted EPOCH (etoposide 200 mg/m², vincristine 1.6 mg/m², cyclophosphamide 748 mg/m², doxorubicin 40 mg/m² continuous infusion over 4 days, prednisone 60 mg/m² daily for 5 days) when administered with lopinavir/ritonavir for treatment of anaplastic large-cell lymphoma. (9)
## Metabolism of chemotherapy agents

<table>
<thead>
<tr>
<th>Chemotherapy agent</th>
<th>Metabolism (6, 7)</th>
<th>Possible interaction (6, 7)</th>
<th>Clinical evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Etoposide</strong></td>
<td>CYP 3A4 (main); CYP 2E1, 1A2 (minor)</td>
<td>Possibility of increased levels with 3A4 inhibitors which may increase the risk and severity of mucositis, myelosuppression and transaminitis. Possibility of decreased levels with 3A4 inducers.</td>
<td>Increased risk of etoposide toxicity shown in CDE regimen and PI-based regimen (infections, neutropenia, mucositis) (4, 5). Good tolerability in three cases with lopinavir/ritonavir and either DA-EPOCH or CODOX-M/IVAC for treatment of non-Hodgkin’s lymphoma or Hodgkin’s lymphoma, respectively. (8, 9)</td>
</tr>
<tr>
<td><strong>Carboplatin</strong></td>
<td>Main route of elimination is renal.</td>
<td>Pharmacokinetic interactions unlikely.</td>
<td>No studies or case reports found in the published literature.</td>
</tr>
<tr>
<td><strong>Ifosfamide</strong></td>
<td>CYP 3A4 to active metabolite, neurotoxic metabolite and detoxification. CYP 2B6 is involved in detoxification.</td>
<td>Inhibition of CYP 3A4 may inhibit drug activation. Induction of CYP 3A4 may increase activation of ifosfamide but may also produce more potentially neurotoxic metabolites.</td>
<td>No ifosfamide toxicity reported in one case where CODOX-M/IVAC was administered with lopinavir/ritonavir for treatment of Burkitt’s lymphoma. (8)</td>
</tr>
<tr>
<td><strong>Mesna</strong></td>
<td>Rapidly oxidized in plasma to dimesna and eliminated renally. No hepatic metabolism. (10)</td>
<td>Pharmacokinetic interactions unlikely.</td>
<td>No mesna toxicity reported in one case where CODOX-M/IVAC was administered with lopinavir/ritonavir for treatment of Burkitt’s lymphoma. (8)</td>
</tr>
</tbody>
</table>

Please consult [http://hivclinic.ca/main/drugs_interact.html](http://hivclinic.ca/main/drugs_interact.html) for more updated information.
Antiretroviral-Chemotherapy Interactions: ICE Regimen

References


1 Enzyme inhibitors include protease inhibitors (PIs): Crixivan® (indinavir), Invirase® (saquinavir), Kaletra® (lopinavir/ritonavir), Norvir®, Norvir sec® (ritonavir), Prezista® (darunavir), Reyataz® (atazanavir), Telzir® (fosamprenavir), Viracept® (nelfinavir); and the integrase inhibitor elvitegravir/cobicistat: available as a coformulated product with tenofovir/emtricitabine (Stribild®); pharmacokinetic enhancer cobicistat (Tybost®).

2 Enzyme inducers include non-nucleoside reverse transcriptase inhibitors (NNRTIs): Atripla® (efavirenz/tenofovir/emtricitabine), Complera® (rilpivirine/tenofovir/emtricitabine), Edurant® (rilpivirine), Intelence® (etravirine), Sustiva® (efavirenz), Viramune®, Viramune XR® (nevirapine) and the protease inhibitor Aptivus® (tipranavir)

3 Enzyme neutral agents include nucleoside reverse transcriptase inhibitors (NRTIs): 3TC® (lamivudine), Combivir® (lamivudine/zidovudine), Kivexa® (abacavir/lamivudine), Retrovir® (zidovudine), Trizivir® (abacavir/zidovudine/lamivudine), Truvada® (tenofovir/emtricitabine), Videx EC® (didanosine), Zerit® (stavudine); integrase inhibitors Isentress® (raltegravir), Tivicay® (dolutegravir); entry inhibitors Fuzeon® (enfuvirtide), Celsentri® (maraviroc)